Literature DB >> 2916626

Long-term oral contraceptive use does not affect trabecular bone density.

T Lloyd1, J R Buchanan, G R Ursino, C Myers, G Woodward, D R Halbert.   

Abstract

To determine whether long-term exposure to exogenous estrogen in oral contraceptives influences trabecular bone mass in premenopausal women, we studied 25 closely matched, healthy, premenopausal women, who were recruited from an active obstetrics and gynecology practice. Eleven women had never used oral contraceptives, and 14 women had used oral contraceptives for a minimum of 67 months. All oral contraceptive users had used preparations that provided a minimum of 50 micrograms mestranol per day. Trabecular bone density was determined by quantitative single-energy computerized tomography of the L1-3 lumbar vertebral bodies. Trabecular bone density was similar for both the control group and the oral contraceptive users, 160.6 +/- 6.9 versus 161.2 +/- 7.4 mg/ml, respectively. The power to detect a 15% difference in bone density between these two samples was 0.87. We concluded that long-term, premenopausal oral contraceptive use has no effect on vertebral bone density.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--side effects; Demographic Factors; Endocrine System; Estrogens; Family Planning; Hormones; Longterm Effects; Oral Contraceptives--side effects; Physiology; Population; Population Dynamics; Reproductive Control Agents; Research Methodology; Time Factors

Mesh:

Substances:

Year:  1989        PMID: 2916626     DOI: 10.1016/0002-9378(89)90457-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

Review 1.  The physiology of the highly trained female endurance runner.

Authors:  M Burrows; S Bird
Journal:  Sports Med       Date:  2000-10       Impact factor: 11.136

Review 2.  Effects of hormonal contraceptives on bone mineral density.

Authors:  B A Cromer
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

3.  Oral contraception affects osteocalcin serum profiles in young women.

Authors:  R Karlsson; S Eden; B von Schoultz
Journal:  Osteoporos Int       Date:  1992-05       Impact factor: 4.507

4.  Estrogen status and heredity are major determinants of premenopausal bone mass.

Authors:  R Armamento-Villareal; D T Villareal; L V Avioli; R Civitelli
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

5.  Bone mineral density in Norwegian premenopausal women.

Authors:  Elin Kolle; Monica Klungland Torstveit; Jorunn Sundgot-Borgen
Journal:  Osteoporos Int       Date:  2004-10-21       Impact factor: 4.507

Review 6.  Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review.

Authors:  S L Liu; C M Lebrun
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

7.  Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period.

Authors:  M A Hansen; K Overgaard; B J Riis; C Christiansen
Journal:  Osteoporos Int       Date:  1991-02       Impact factor: 4.507

8.  Oral contraceptive treatment inhibits the normal acquisition of bone mineral in skeletally immature young adult female monkeys.

Authors:  T C Register; M J Jayo; C P Jerome
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

9.  Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. European Vertebral Osteoporosis Study Group.

Authors:  T W O'Neill; A J Silman; M Naves Diaz; C Cooper; J Kanis; D Felsenberg
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

10.  Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause.

Authors:  MaryFran R Sowers; Huiyong Zheng; Mary L Jannausch; Daniel McConnell; Bin Nan; Sioban Harlow; John F Randolph
Journal:  J Clin Endocrinol Metab       Date:  2010-03-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.